Skip to main content

Table 2 Gene expression and prognostic factors of ccRCC

From: Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics

  mTOR VEGFR1 VEGFR2 VEGFA HIF1A PDGF VHL
Low (n = 18) 0.63(1.32) 1.96(2.10) 3.17(6.12) 11.87 (16.14) 1.56 (2.27) 5.91 (11.18) 0.29 (1.04)
Intermediate (n = 29) 1.32 (5.43) 1.84(4.85) 1.11(1.38) 7.10 (4.47) 1.05 (1.29) 4.27 (9.39) 18.28 (87.65)
High n = 9 0.55 (0.63) 4.48(6.10) 1.51(2.26) 4.20 (4.58) 3.12 (5.58) 7.05 (9.53) 5.18 (6.73)
p 0.82b 0.37b 0.89b 0.18b 0.43b 0.76b 0.67b
Size ≥7 cm (n = 30) 0.52 (1.11) 1.74 (2.06) 2.41 (5.14) 10.33 (13,53) 1.27 (1.97) 6.62 (12.76) 0.39 (1.20)
Size <7 cm (n = 26) 1.54 (5.84) 2.69 (5.81) 1.31 (1.72) 6.32 (4.45) 1.74 (3.10) 3.56 (5.17) 18.84 (85.70)
p 0.97a 0.59a 0.87a 0.17a 0.50a 0.97a 0.12a
MVI absent (n = 44) 0.45 (0.95) 2.03(4.11) 2.08 (4.27) 9.77 (11.28) 1.10(1.63) 5.24(10.57) 12.54(72.60)
MVI present (n = 12) 3.39 (9.18) 2.75(4.76) 1.10 (1.71) 3.61(3.57) 2.91(4.36) 4.89(7.41) 3.66(5.73)
p 0.25a 0.61a 0.46a 0.57a 0.08a 0.91a 0.68a
Fuhrman’s Grade I e II (n = 32) 1.43 (5.32) 1.57 (1.79) 2.43 (4.97) 9.86 (13.09) 1.54 (2.11) 4.39 (9.21) 0.19 (0.84)
Fuhrman’s Grade III e IV (n = 24) 0.40 (0.52) 3.00 (6.10) 1.19 (1.68) 6.57 (4.81) 1.45 (3.06) 6.17 (10.97) 20.65 (89.28)
p 0.81a 0.45a 0.56a 0.26a 0.89a 0.51a 0.13a
Metastasis Absent (n = 48) 0.46(0.93) 1.81 (2.86) 1.96 (4.14) 8.53 (11.20) 1.54(2.76) 5.59 (10.78) 1.18 (3.44)
Metastasis Present (n = 8) 3.64(9.71) 4.03 (8.24) 1.41 (2.10) 7.98(4.54) 1.27(1.20) 3.05(3.04) 54.33(151.70)
p 0.82a 0.49a 0.71a 0.89a 0.77a 0.49a 0.79a
pT1–2 (n = 26) 0.51 (1.16) 1.33 (1.74) 2.47 (5.31) 10.12 (14.05) 1.47 (2.13) 7.07 (13.16) 0.20 (0.86)
pT3–4 (n = 30) 1.48 (5.62) 3.03 (5.63) 1.33 (1.72) 6.83 (4.67) 1.53 (2.95) 3.34 (4.95) 19.00 (85.67)
p 0.38a 0.51a 0.97a 0.26a 0.80a 0.16a 0.18a
  1. aMann-Whitney test b Kruskall-Wallis Test